文献速递复苏、休克与脓毒症重症综合管理与镇静镇痛

乳酸林格液对比含4%白蛋白乳酸林格液在癌症患者早期脓毒症治疗中的单中心随机先导试验

Lactated Ringer's Versus 4% Albumin on Lactated Ringer's in Early Sepsis Therapy in Cancer Patients: A Pilot Single-Center Randomized Trial.
PubMed 文献 · Crit Care Med · 2019-01-01
一句话结论在癌症合并严重脓毒症或脓毒性休克患者中,早期液体复苏时在乳酸林格液中加入4%白蛋白未能改善7天生存。

该单中心、随机、双盲、平行对照先导试验于2014年10月至2016年12月纳入360例癌症合并严重脓毒症或脓毒性休克患者。患者被随机分配至接受乳酸林格液+4%白蛋白或单纯乳酸林格液进行ICU入科后前6小时液体复苏。主要终点7天全因死亡:白蛋白组26%(46/180)vs 乳酸林格液组22%(40/180),p=0.5;28天全因死亡:白蛋白组53%(96/180)vs 乳酸林格液组46%(83/180),p=0.2。次要终点均无显著差异。作者结论:在癌症脓毒症患者早期标准乳酸林格液复苏中加入白蛋白未改善7天生存。

要点

  • 癌症合并严重脓毒症或脓毒性休克患者,ICU入科后前6小时液体复苏时在乳酸林格液中加入4%白蛋白,7天全因死亡为26%(46/180)vs 单纯乳酸林格液22%(40/180),p=0.5。
  • 28天全因死亡为白蛋白组53%(96/180)vs 乳酸林格液组46%(83/180),p=0.2。
  • SOFA评分从基线至第7天的变化、无机械通气天数、无血管加压药天数、ICU期间肾脏替代治疗、ICU住院时间及住院时间等次要终点均无显著差异。
  • 作者结论:在癌症脓毒症患者早期标准乳酸林格液复苏中加入白蛋白未改善7天生存。

适用人群与场景

  • 癌症合并严重脓毒症或脓毒性休克患者,入住三级大学癌症医院ICU。
  • 研究时间为2014年10月至2016年12月。

处置流程与药物剂量

  • 在ICU入科后前6小时液体复苏期间,随机给予乳酸林格液+4%白蛋白的bolus(原文未写明剂量、给药间隔)或单纯乳酸林格液。

研究设计与关键结果

  • 研究设计:单中心、随机、双盲、平行对照先导试验,纳入360例癌症合并严重脓毒症或脓毒性休克患者。
  • 主要终点7天全因死亡:白蛋白组26%(46/180)vs 乳酸林格液组22%(40/180),p=0.5。
  • 28天全因死亡:白蛋白组53%(96/180)vs 乳酸林格液组46%(83/180),p=0.2。
  • 次要终点(SOFA评分从基线至第7天变化、无机械通气天数、无血管加压药天数、ICU期间肾脏替代治疗、ICU住院时间及住院时间)均无显著差异。

证据类型、等级与局限

  • 证据类型:单中心、随机、双盲、平行对照先导试验。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者结论:在癌症脓毒症患者早期标准乳酸林格液复苏中加入白蛋白未改善7天生存。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

OBJECTIVE: To investigate the effects of the administration of 4% albumin on lactated Ringer's, when compared with lactated Ringer's alone, in the early phase of sepsis in cancer patients.

DESIGN: Single-center, randomized, double-blind, controlled-parallel trial.

SETTING: A tertiary care university cancer hospital.

PATIENTS: Cancer patients with severe sepsis or septic shock.

INTERVENTIONS: Between October 2014 and December 2016, patients were randomly assigned to receive either bolus of albumin in a lactated Ringer's solution or lactated Ringer's solution alone during the first 6 hours of fluid resuscitation after intensive care medicine (ICU) admission. Primary outcome was defined as death from any cause at 7 days. Secondary outcomes were defined as death from any cause within 28 days, change in Sequence Organ Failure Assessment scores from baseline to day 7, days alive and free of mechanical ventilation, days alive and free of vasopressor, renal replacement therapy during ICU stay, and length of ICU and hospital stay.

MEASUREMENTS AND MAIN RESULTS: A total of 360 patients were enrolled in the trial. At 7 days, 46 of 180 patients (26%) died in the albumin group and 40 of 180 (22%) died in the lactated Ringer's group (p = 0.5). At 28 days, 96 of 180 patients (53%) died in the albumin group and 83 of 180 (46%) died in the lactated Ringer's group (p = 0.2). No significant differences in secondary outcomes were observed.

CONCLUSIONS: Adding albumin to early standard resuscitation with lactated Ringer's in cancer patients with sepsis did not improve 7-day survival.

来源:Crit Care Med,查看原文。版权归原作者所有。

参考来源

  1. Park CHL, de Almeida JP, de Oliveira GQ, et al. Lactated Ringer's Versus 4% Albumin on Lactated Ringer's in Early Sepsis Therapy in Cancer Patients: A Pilot Single-Center Randomized Trial. Crit Care Med. 2019. PMID: 31356475. doi:10.1097/CCM.0000000000003900

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。